Scientific Publications by FDA Staff
Clin Infect Dis 2010 May 1;50(9):1252-5
Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts.
Memoli MJ, Hrabal RJ, Hassantoufighi A, Eichelberger MC, Taubenberger JK
Pandemic 2009 H1N1 virus isolates containing the neuraminidase inhibitor resistance mutation H275Y have been reported. We describe rapid selection for the H275Y resistance mutation during therapy in 2 immunocompromised individuals at 9 and 14 days of therapy, as well as the first described case of clinically significant resistance to peramivir.
|Category: Journal Article|
|PubMed ID: #20345239||DOI: 10.1086/651605|
|Includes FDA Authors from Scientific Area(s): Biologics|
|Entry Created: 2011-10-04||Entry Last Modified: 2012-08-29|